

10/584109

AP3 Rec'd PCT/PTO 22 JUN 2008

Sheet 1 of 2

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20381-003US1	Application No. To Be Assigned
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kenichiro Kosai et al.	
		Filing Date Herewith	Group Art Unit

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AJ							
	AK							
	AL							
	AM							
	AN	0						

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AO	Berdichevski, F., "Complexes of Tetraspanins with Integrins: More than Meets the Eye", <i>Journal of Cell Science</i> , Vol. 114, pp. 4143-4151, 2001.
	AP	Dominguez-Jimenez, C. et al., "Involvement of α3 Integrin/Tetraspanin Complexes in the Angiogenic Response Induced by Angiotensin II", <i>FASEB Journal</i> , Vol 15, pp. 1457-1459, 2001.
	AQ	Hashida, H. et al., "Clinical Significance of Transmembrane 4 Superfamily in Colon Cancer", <i>British journal of Cancer</i> , Vol. 89, pp. 158-167, 2003
	AR	Higashiyama, S. et al., "The Membrane Protein CD9/DRAP 27 Potentiates the Juxtacrine Growth Factor Activity of the Membrane-anchored Heparin-binding EGF-like Growth Factor", <i>The journal of Cell Biology</i> , Vol. 128, pp. 929-938, 1995.
	AS	Iwamoto, R and Mekada E., "Heparin-binding EGF-like Growth Factor: A Juxtacrine Growth Factor", <i>Cytokine & Growth Factor Reviews</i> , Vol. 11, pp. 335-344, 2000.

Examiner Signature /Sumesh Kaushal/	Date Considered (06/23/2008)
--	---------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SK/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20381-003US1	Application No. To Be Assigned
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kenichiro Kosai et al.	
		Filing Date Herewith	Group Art Unit

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AT	Iwamoto, R. et al., "Heparin-binding EGF-like Growth Factor and ErbB Signaling is Essential for Heart Function", <i>PNAS</i> , Vol. 100, No. 6, pp. 3221-3226, 2003.
	AU	Jennings, L. K. et al., "The Activation of Human Platelets Mediated by Anti-human Platelet p24/CD9 Monoclonal Antibodies", <i>The Journal of Biological Chemistry</i> , Vol. 265, No. 7, pp. 3815-3822, 1990.
	AV	Kirkland, G. et al., "Heparin-Binding EGF-Like Growth Factor mRNA Is Upregulated in the Peri-Infarct Region of the Remnant Kidney Model: <i>In Vitro</i> Evidence Suggests a Regulatory Role in Myofibroblast Transformation", <i>Journal of the American Society of Nephrology</i> , Vol. 9, pp. 1464-1473, 1998.
	AW	Klein-Soyer, C. et al. "CD9 Participates in Endothelial Cell Migration During <i>In Vitro</i> Wound Repair", <i>Arterioscler. Thromb. Vasc Biol.</i> , Vol. 20, pp. 360-369, 2000.
	AX	Maecker, H. T. et al., "The Tetraspanin Superfamily: Molecular Facilitators", <i>The FASEB Journal</i> , Vol. 11, pp. 428-442, 1997.
	AY	Masellis-Smith, A. et al., "Anti-CD9 Monoclonal Antibodies Induce Homotypic Adhesion of PRE-B Cell Lines by A Novel Mechanism", <i>The Journal of Immunology</i> , Vol. 144, No. 5, pp. 1607-1613, 1990.
	AZ	Miyado, K. et al., "Requirements of CD9 on the Egg Plasma Membrane for fertilization", <i>Science</i> , vol. 287, pp. 321-324, 2000.
	AAA	Miyagawa, J.-i. et al., "Localization of Heparin-binding EGF-like Growth Factor in the Smooth Muscle Cells and Macrophages of Human Atherosclerotic Plaques", <i>J. Clin. Invest.</i> , Vol. 95, pp. 404-411, 1995.
	ABB	Morimoto, C. et al., "Epidermal Growth Factor: EGF (Heparin-binding EGF-like Growth Factor: HB-EGF)", <i>Clinical Endocrinology</i> , Vol. 51, No. 12, 1137-1143, 2003.
	ACC	Nakagawa, T. et al., "Amino-terminal Processing of Cell Surface Heparin-binding Epidermal Growth Factor-like Growth Factor Up-regulates Its Juxtacrine but Not its Paracrine Growth Factor Activity", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 48, pp. 30858-30863, 1996.
	ADD	Nakamura, K. et al., "Importance of the Major Extracellular Domain of CD9 and the Epidermal Growth Factor (EGF)-like Domain of Heparin-binding EGF-like Growth Factor for Up-regulation of Binding and Activity", <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 24, pp. 18284-18290, 2000.
	AEE	Nakamura, Y. et al., "Immunohistochemical Distribution of CD9, Heparin Binding Epidermal Growth Factor-like Growth Factor, and Integrin $\alpha 3 \beta 1$ in Normal Human Tissues", <i>The Journal of Histochemistry & Cytochemistry</i> , Vol. 49, No. 4, pp. 439-444, 2001.
	AFF	Nakata, A. et al., "Localization of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Coronary Arteries", <i>Circulation</i> , vol. 94, pp. 2778-2786, 1996.
	AGG	Nishida, M. et al., "Localization of CD9, an Enhancer Protein for Proheparin-Binding Epidermal Growth Factor-Like Growth Factor, in Human Atherosclerotic Plaques", <i>Arterioscler Thromb Vasc Biol.</i> , Vol. 20, pp. 1236-1243, 2000.
	AHH	Takemura, T. et al., "Coexpression of CD9 Augments the Ability of Membrane-bound Heparin-binding Epidermal Growth Factor-like Growth Factor (pro HB-EGF) to Preserve Renal Epithelial Cell Viability", <i>Kidney International</i> , Vol. 55, pp. 71-81, 1999.

Examiner Signature /Sumesh Kaushal/	Date Considered 06/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	